A late-stage study of Novartis' multiple sclerosis drug Mayzent showed patients' cognitive skills improved versus with a placebo. The company has FDA approval for the drug.
Novartis' Mayzent shows promise in boosting cognitive skills in MS
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.